Cytosorbents (CTSO) Income from Continuing Operations (2010 - 2026)

Cytosorbents (CTSO) has reported Income from Continuing Operations for 17 consecutive years, with -$3.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations rose 17.14% year-over-year to -$3.5 million; the trailing twelve-month figure through Jun 2026 stood at -$15.7 million (up 2.28% YoY), and the FY2025 full-year result was -$7.8 million, up 62.34% from the prior year.
• Income from Continuing Operations climbed to -$3.5 million in Q2 2026 per CTSO's latest filing, from -$3.9 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at -$766126.0 in Q4 2022 and bottomed at -$12.2 million in Q3 2022.
• Historically, Income from Continuing Operations has averaged -$5.8 million across 5 years, with a median of -$5.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations jumped 91.77% in 2022, then slumped 758.12% in 2023.
• Over 5 years, Income from Continuing Operations stood at -$766126.0 in 2022, then plunged by 758.12% to -$6.6 million in 2023, then decreased by 15.1% to -$7.6 million in 2024, then soared by 32.59% to -$5.1 million in 2025, then soared by 31.27% to -$3.5 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered -$3.5 million, -$3.9 million, and -$5.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.